Company Overview and News

 
KLCI stays negative, falls 0.43%

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): The FBM KLCI remained in the negative zone at the midday break today, and fell 0.43% in line with the decline at regional markets.
UPBMF 5088 7113 5010 TPGVF 5202 2089 9334 6033 5199 9113 TGLVY 0143 5139 4588 PNADF 3867 0900 6888 AXXTF 2836 HIPEF PNAGF

 
Stock With Momentum: Sanbumi Holdings

2018-10-05 theedgemarkets
Sanbumi Holdings Bhd (-ve) TRADING of shares in Sanbumi Holdings Bhd (fundamental: 1.65/3, valuation: 0.9/3) triggered our momentum algorithm yesterday for the eighth time this year. The stock closed up 8.5 sen or 38.64% at 30.5 sen, with a market capitalisation of RM69.04 million. The counter saw 39.64 million shares done, versus its 200-day average trading volume of 228,089 shares.
9113

 
KLCI falls 0.38% in tandem with regional retreat

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): The FBM KLCI fell 0.38% at mid-morning today, tracking fragile regional markets.
UPBMF 7113 TPGVF BATS 4162 2291 5202 2089 9334 6033 9113 4634 TGLVY 5139 PNADF 5226 3301 NDAQ 0900 6888 5819 AXXTF 1902 PNAGF

 
Iconic chairman Tan raises equity in Sanbumi

2018-10-03 thestar.com.my
Sanbumi, in a filing with Bursa Malaysia, said the company had entered into a conditional share subscription agreement with Tan for the placement of 22.6 million new shares at 17.3 sen each.
BSMAF 1818 9113

2
KLCI to track global markets, seen hovering below 1,800-point level

2018-10-02 theedgemarkets
KUALA LUMPUR (Oct 3): The FBM KLCI is seen hovering below the 1,800-point level today,tracking the overnight close at most gobal markets, exacerbated by tepid local investor sentiment.
0078 0143 5236 7811 MGFCF MSCI 9113

 
Key ASIC, GDex, Malakoff, DRB-Hicom, MHB, Malton, Matrix, Mega First, Sanbumi and Sapura Industrial

2018-10-02 theedgemarkets
KUALA LUMPUR (Oct 2): Based on corporate announcements and news flow today, companies in focus on Wednesday (Oct 3) may include: Key ASIC Bhd, GD Express Carrier Bhd, Malakoff Corp Bhd, DRB-Hicom Bhd, Malaysia Marine and Heavy Engineering Holdings Bhd, Malton Bhd, Matrix Concepts Holdings Bhd, Mega First Corp Bhd, Sanbumi Holdings Bhd and Sapura Industrial Bhd.
0078 0143 5236 7811 MGFCF 9113

 
Sanbumi to raise RM3.9m via placement of shares to founder

2018-10-02 theedgemarkets
KUALA LUMPUR (Oct 2): Sanbumi Holdings Bhd has proposed to place out new shares to Penang-based property developer Iconic Group Sdn Bhd founder and chairman Datuk Tan Kean Tet to raise about RM3.92 million for working capital and/or future business project(s) or investment(s).
9113

 
Stock With Momentum: Sanbumi Holdings

2018-09-18 theedgemarkets
Sanbumi Holdings Bhd (-ve) TRADING of shares in Sanbumi Holdings Bhd (fundamental: 1.65/3, valuation: 0.9/3) triggered our momentum algorithm last Friday for the fifth time this year.
9113

 
Stock With Momentum: Sanbumi Holdings

2018-09-06 theedgemarkets
Sanbumi Holdings Bhd (-ve) TRADING of shares in Sanbumi Holdings Bhd (fundamental: 1.65/3, valuation: 0.9/3) triggered our momentum algorithm yesterday for the fourth time this year.
9113

 
Stock With Momentum: Sanbumi Holdings

2018-08-30 theedgemarkets
TRADING in the shares of Sanbumi Holdings (fundamental: 1.65/3, valuation: 0.90/3) triggered our momentum algorithm yesterday for the first time this year.
9113

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...